into false positive responses
play

into False Positive Responses in the Local Lymph Node Assay (LLNA) - PowerPoint PPT Presentation

Toxicogenomic Investigation into False Positive Responses in the Local Lymph Node Assay (LLNA) Darrell Boverhof, Ph.D. Toxicology & Environmental Research and Consulting (TERC) The Dow Chemical Company Midland, MI Rboverhof@dow.com 1


  1. Toxicogenomic Investigation into False Positive Responses in the Local Lymph Node Assay (LLNA) Darrell Boverhof, Ph.D. Toxicology & Environmental Research and Consulting (TERC) The Dow Chemical Company Midland, MI Rboverhof@dow.com 1

  2. Acknowledgements Study supported by:  DOW  CEFIC-LRI  David Adenuga  Michael Woolhiser  Bhaskar Gollapudi  Lindsay Sosinski  Rachel Golden  University of Manchester, UK  Ian Kimber  Rebecca Dearman  The Hamner Institutes for Health Sciences  Russell Thomas  Michael Black 2

  3. Background- Allergic Contact Dermatitis GPMT (Guinea pig maximization test) LLNA Proliferation/memory T-cells 3 http://sensitive-learning.eu/mod/resource/view.php?id=77

  4. Background- Local Lymph Node Assay  Assay which detects the contact sensitization potential of chemicals (sensitization phase) Dorsal 3 H-thymidine Incorporated 3 H-thymidine Incorporated surface of into DNA of dividing cells into DNA of dividing cells Sensitization / Sensitization / ears Lymph Node Lymph Node Proliferation Proliferation Rest Rest 5 hours 5 hours Days 4, 5 Days 4, 5 Treat Treat Inject 3 H-thymidine Inject 3 H-thymidine Remove Lymph Nodes Remove Lymph Nodes Days 1, 2, 3 Days 1, 2, 3 Day 6 Day 6 Day 6 Day 6 Auricular Nodes Auricular Nodes  Reported as a stimulation index (SI) Prepare Single, Prepare Single,  Ratio Treatment/Vehicle Cell Suspension Cell Suspension  Cutoff for positive response SI >= 3 Measure 3 H-thymidine Incorporation Measure 3 H-thymidine Incorporation 4

  5. The Problem of False Positive Chemistries in the LLNA

  6. The Problem of False Positive Chemistries in the LLNA  Can differential gene expression responses (toxicogenomics) in the lymph node be applied to distinguish true sensitizers from false positives in the LLNA?  Functional insights into different mechanisms  Development of molecular classifiers to distinguish between these two classes 6

  7. Study Approach  Critical Elements:  Chemical Selection  Selection of false positive chemistries  # of Chemistries  Dose  All chemicals tested at equipotent doses in LLNA  Time  Examined multiple time points  Comprehensive  Anchor gene expression responses to traditional LLNA endpoint  2 Phases- Development and Confirmation 7

  8. Study Approach- Comprehensive  Phase 1  9 Sensitizers  7 False positives  Functional evaluation of differential gene expression  Whole genome array  Molecular classifier development and assessment  Phase 2  6 Sensitizers  6 False Positives  Confirmation of functional gene expression responses  Focused QRTPCR arrays  Evaluation of classifier performance 8

  9. Phase 1 Test Materials Sensitizer Class Test Material Vehicle Dose Dinitrochlorobenzene (DNCB) Acetone 0.10% Hexylcinnamic aldehyde (HCA) Acetone 25% Isoeugenol Acetone 10% para -phenylene diamine(PPD) Acetone 1% Sensitizers Hydroquinone (HQ) Acetone 0.25% Methyldibromo glutaronitrile (MDBGN) Acetone 20% Toluene diisocyanate (TDI) Acetone 0.04% Trimellitic anhydride (TMA) Acetone 0.65% Ammonium Hexachloroplatinate (AHCP) DMSO 0.70% Oleic acid DMSO 50% Maleic acid DMSO 11.50% Sodium lauryl sulphate (SLS) DMSO 25% Presumptive Tetraethylene glycol Monotetradecyl ether (TGME) Acetone 20% False Positives Polyaminofunctional siloxane Acetone 45% N-decylphenol polyethyleneglycol ether (DPP) Acetone 35% Hexadecan-1-ol Ethoxylated (EO2) C16 (HDE) Acetone 30%  Equipotent doses (SI 6-9) calculated based on results from screening LLNA 9

  10. Phase 1- Stimulation Index response 10

  11. Phase 1- Toxicogenomic evaluation  Test materials grouped into a 3 class coding scheme –  Vehicles controls Isolate Auricular nodes Isolate Auricular nodes  Sensitizers  False positives Isolate RNA Isolate RNA Isolate RNA Cy3 Cy3 Cy3 Cy3 Reverse Reverse Reverse  Data filtered on expression ( ± 1.5 Transcription Transcription Transcription FC) and 2 way ANOVA linear contrasts (FDR < 0.05) Hybridize on array Hybridize on array  Commonly regulated genes  Responses unique to Sens and FP  Functional evaluation- Gene Data Extraction and Data Extraction and Analysis Analysis Ontology 11

  12. Toxicogenomic evaluation Commonly Expressed Genes Genes similarly regulated by sensitizers and false positives relative to controls  Functional Categories involved in Cell Proliferation  Initiation of mitosis  Cell cycle regulation  The metaphase checkpoint  Chromosome condensation in prometaphase  Spindle assembly and chromosome separation o Indicates both Sensitizers and False positives induce a LN proliferative response o Offer no ability to discriminate between sensitizers and false positives 12

  13. Toxicogenomic evaluation Sensitizer-Specific Genes 4 Genes Fxyd4 Thbs4 differentially Normalized Mean Intensity (Log 2 ) Cphx Lgals7 regulated by 2 Il21 Sens relative to both FPs and Controls 0 -2 Vehicles Sensitizers False Positives -4 Untreated Acetone DMSO AHCP TDI TMA DNCB HCA HQ Isoeugenol PPD MDBGN DPP HDE Siloxane TGME Maleic Oleic SLS Key functional categories – 1. Positive regulation of immune system process 2. Leukocyte activation and migration 13

  14. Toxicogenomic evaluation False Positive-Specific Genes Genes differentially regulated by FPs relative to both Sens and Controls Key functional categories – 1. Acute inflammatory response 2. Innate defense response (Neut/Mac markers – Mpo, Lcn2) 14

  15. Phase 2 Test Materials Sensitizer Class Test Material Conc. DNCB 0.05% Benzoquinone (BZQ) 0.10% 2-hydroxyethyl acrylate (2-HEA) 20% Sensitizers Phenyl acetaldehyde (PA) 20% Citral 30% Propyl Gallate (PG) 3% DPP 35% Benzalkonium Chloride (BZC) 1% Presumptive Squalene 50% False Positives Methyl Oleate (MO) 50% Hexaethylene glycol monododecyl ether (HGME) 25% Linolenic Acid (LA) 50%  Equipotent doses (SI 6-9) calculated based on results from screening LLNA 15

  16. Phase 2- Stimulation Index response SI=3 Stimulation Index 10 15 0 5 Acetone DNCB Sensitizers BZQ 2-HEA PA Citral PG DPP False Positives BZC Squalene MO HGME LA

  17. Phase 2 Sensitizer-Specific Genes 15 Cphx Il21 Lgals7 12 Thbs4 Fold change to Veh 9 6 3 0 DNCB BQ 2-HEA PA Citral Propyl galate DPP Benzalk Cl Squalene Me oleate HGME Linoleic acid Sensitizers False Positives Key functional categories – 1. Positive regulation of immune system process 2. Leukocyte activation and migration 17

  18. Phase 2 False Positive-Specific Genes 18 Cd5l 15 Dao Defa-rs2 Il12b Fold change to Veh Syn3 12 9 6 3 0 DNCB BQ 2-HEA PA Citral Propyl galate DPP Benzalk Cl Squalene Me oleate HGME Linoleic acid Sensitizers False Positives Key functional categories – 1. Acute inflammatory response 2. Innate defense response (Neut/Mac markers – Mpo, Lcn2) 18

  19. Development of Statistical Classifiers- Phase 1 Total of 50 iterations Gene Expression Microarrays Select Features Averaged parameter values Build Partition Set 1 Set provide broad- Model Aside Data into 5 based evaluation Sets Predict of predictive Hold- performance Out Set Accuracy Sensitivity Specificity AUC Repeat 10X – Tested in a total of 84 optimized models 19

  20. Development and Evaluation of Statistical Classifiers PHASE 1 30 genes PHASE 2

  21. Summary/Conclusions  Sensitizer- and False Positive-specific gene expression responses were identified  Sens- antigen-mediated T-cell response.  FPs- consistent with a pro-inflammatory response  Class-specific gene expression responses were reproducible in an independent experiment  Molecular classifiers were developed that had very good performance  Genes that made up the classifier were consistent with those identified through the functional analysis  Approach could be used as part of a WoE analysis for suspected false positives 21

  22. Acknowledgements Study supported by:  DOW  CEFIC-LRI  David Adenuga  Michael Woolhiser  Bhaskar Gollapudi  Lindsay Sosinski  Rachel Golden  University of Manchester, UK  Ian Kimber  Rebecca Dearman  The Hamner Institutes for Health Sciences  Russell Thomas  Michael Black 22

Recommend


More recommend